US to End Funding for South Africa’s HIV Programs Amid Claims of Persecution

The U.S. government has announced it will end funding for South Africa’s HIV programmes under the President’s Emergency Plan for AIDS Relief (PEPFAR), citing allegations of persecution against Afrikaners in the country. The decision, confirmed by multiple sources including the BBC, Semafor, and Politico, marks a significant shift in U.S. foreign aid policy and comes amid rising diplomatic tensions between Washington and Pretoria.

According to the BBC, the Trump administration has directed PEPFAR to phase out financial support for South Africa’s HIV initiatives, a move that officials say stems from concerns over the treatment of Afrikaners—particularly white farmers—under President Cyril Ramaphosa’s government. The decision follows a series of reports detailing violence and land seizures targeting white South Africans, which U.S. lawmakers and advocacy groups have framed as ethnic persecution. A senior administration official, speaking on condition of anonymity, told Semafor that the funding cutoff is “directly tied to the deteriorating human rights situation for Afrikaners,” though no specific incidents were cited in the announcement.

PEPFAR, established in 2003 under President George W. Bush, has been a cornerstone of global HIV/AIDS response, allocating over $100 billion to combat the epidemic in more than 50 countries. South Africa, the hardest-hit nation by HIV infections, has received billions in U.S. aid since 2004. The BBC reports that the funding freeze affects not only direct grants but also technical assistance and supply chains for antiretroviral treatments, which treat over 5 million South Africans annually. The move risks disrupting care for thousands, with health experts warning of potential treatment gaps.

Why is the U.S. cutting funding now?

The timing of the announcement aligns with a broader U.S. push to link foreign aid to human rights conditions, a strategy revived under the Trump administration. In 2020, the U.S. suspended $1.2 billion in military aid to South Africa over similar concerns, though that decision was later reversed. This latest action, however, targets health funding—a far more sensitive area given South Africa’s reliance on international support for its HIV response.

South African officials have denied allegations of systemic persecution, with Foreign Minister Naledi Pandor telling reporters last month that the government “rejects any claims of ethnic targeting.” Yet internal U.S. cables obtained by Semafor reveal that the State Department has escalated concerns over “patterned violence” against white farmers, including arson attacks and land invasions. The BBC notes that the U.S. has also pressured South Africa over its handling of crime and corruption, though the HIV funding decision appears primarily driven by Afrikaner rights advocacy.

What happens next for South Africa’s HIV programmes?

With PEPFAR funding set to expire by the end of 2024, South Africa’s health ministry is scrambling to secure alternative financing. The country’s National Department of Health confirmed to Politico that it has begun “emergency discussions” with the World Health Organization and the Global Fund to bridge the gap. However, officials acknowledge that replacing $1.5 billion in annual U.S. support will be “extremely challenging,” particularly as global aid budgets tighten.

Dr. Salim Abdool Karim, a leading South African epidemiologist, warned in a statement to the BBC that the funding cutoff could reverse decades of progress. “South Africa’s HIV response is one of the most advanced in the world, but it relies heavily on international partnerships,” he said. “A sudden withdrawal of PEPFAR support would force us to ration treatments—a crisis we’ve already faced in the past.” The BBC reports that local NGOs have already begun stockpiling medicines in anticipation of potential shortages.

How does this compare to past U.S. aid cuts?

This is not the first time the U.S. has conditioned aid on human rights concerns. In 2017, the Trump administration suspended funding to Palestinian groups over allegations of anti-Semitism, and in 2021, it withheld military aid to Myanmar following a coup. However, the HIV funding decision stands out for its direct impact on a public health crisis. Unlike those cases, where aid was symbolic or tied to security, PEPFAR’s work in South Africa is lifesaving—treating 85% of those in need of antiretroviral therapy.

A comparison of recent U.S. aid suspensions shows a pattern of tying assistance to domestic political pressures. The Afrikaner rights movement in the U.S., led by groups like the Heritage Foundation, has lobbied aggressively for action, framing South Africa’s policies as “apartheid 2.0.” While the Biden administration has not yet signaled whether it will reverse the decision, a State Department spokesperson told Politico that “any future aid will depend on demonstrable improvements in human rights and rule of law.”

What’s the reaction from South Africa’s allies?

The funding cut has drawn sharp criticism from South Africa’s traditional partners. The European Union, which co-funds HIV programmes in the country, has urged the U.S. to “reconsider its approach,” with a spokesperson stating that “health is not a political tool.” Meanwhile, the African Union’s health commissioner, Dr. Matshidiso Moeti, called the decision “a setback for global health solidarity,” adding that it “undermines trust in international cooperation.”

China, which has expanded its medical aid presence in Africa, has not yet commented publicly but has historically filled gaps left by Western donors. A source familiar with Beijing’s health diplomacy told Semafor that China is “monitoring the situation closely” and may offer limited support—though not at the scale of PEPFAR. For now, South Africa’s options remain constrained, with domestic funding already stretched thin by economic struggles.

The U.S. Embassy in Pretoria has not confirmed a timeline for the funding phase-out, though sources suggest the process could take months. With no immediate resolution in sight, health officials and activists are bracing for a prolonged uncertainty—one that risks leaving millions without critical care.